Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.039752 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Shea Hogan und 13 weiteren Autor:innen. Beteiligte Einrichtung: CPC Clinical Research Aurora CO USA. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Lower Extremity, Peripheral Arterial Disease, Rivaroxaban. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities) demonstrated that antiplatelet therapy with rivaroxaban 2.5 mg twice daily compared with placebo reduced the first event in a composite end point in patients with peripheral artery disease after revascularization. The purpose of this analysis was to (1) evaluate whether rivaroxaban decreased the most severe events and (2) compare the harm and benefit of rivaroxaban on the same scale.
Methods
Two exploratory, hierarchical analyses of the primary efficacy composite outcome and one exploratory analysis of the net clinical benefit composite outcome were prespecified. The global rank method and the win ratio method ranked components of the composite outcome by clinical importance. The net clinical benefit included both efficacy and safety outcomes.
Results
The global rank method demonstrated that participants on rivaroxaban had fewer or later events than their placebo counterparts when events were compared in a hierarchical manner (primary ranking, P =0.0158). The win ratio approach demonstrated fewer or later fatal and nonfatal ischemic events in the rivaroxaban arm (win ratio, 1.16 [95% CI, 1.03–1.30]; P =0.0167). The net clinical benefit analysis revealed an overall beneficial effect of rivaroxaban when different efficacy and safety end points were included ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CPC Clinical Research Aurora CO USA.
- Denver Health Denver CO USA.
- Department of Medicine University of Colorado Aurora CO USA.
- Downstate Health Sciences University School of Public Health Brooklyn NY USA.
- University Heart & Vascular Center Hamburg-Eppendorf Hamburg Germany.
- Department of Surgery University of Colorado Aurora CO USA.
ORCID-Profile: Shea Hogan, Michael Szarek, E Sebastian Debus, Mark Nehler, Sonia S Anand, Manesh R Patel, Akos Ferenc Pap, Lloyd P Haskell, Eva Muehlhofer, Scott E Berkowitz, Rupert M Bauersachs, Marc P Bonaca
Zitieren
APA
Hogan, S., Szarek, M., Debus, E. S., Nehler, M., Anand, S. S., Patel, M. R., Pap, A. F., Deng, H., Hodge, S., Haskell, L. P., Muehlhofer, E., Berkowitz, S. E., Bauersachs, R. M., & Bonaca, M. P. (2025). Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.039752
Vancouver
Hogan S, Szarek M, Debus ES, Nehler M, Anand SS, Patel MR, et al. Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.039752
BibTeX
@article{Hogan2025,
author = {Hogan, Shea and Szarek, Michael and Debus, E Sebastian and Nehler, Mark and Anand, Sonia S and Patel, Manesh R and Pap, Akos Ferenc and Deng, Hsiaowei and Hodge, Sophie and Haskell, Lloyd P and Muehlhofer, Eva and Berkowitz, Scott E and Bauersachs, Rupert M and Bonaca, Marc P},
title = {Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.039752}
}
EUVIMED